- Home
- ODV vs GLSI Comparison
ODV vs GLSI Comparison
Compare ODV & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODV
- GLSI
- Stock Information
- Founded
- ODV 2005
- GLSI 2006
- Country
- ODV Canada
- GLSI United States
- Employees
- ODV N/A
- GLSI N/A
- Industry
- ODV Precious Metals
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- ODV Basic Materials
- GLSI Health Care
- Exchange
- ODV Nasdaq
- GLSI Nasdaq
- Market Cap
- ODV 204.7M
- GLSI 197.1M
- IPO Year
- ODV N/A
- GLSI 2020
- Fundamental
- Price
- ODV $2.14
- GLSI $14.20
- Analyst Decision
- ODV
- GLSI Strong Buy
- Analyst Count
- ODV 0
- GLSI 1
- Target Price
- ODV N/A
- GLSI $38.00
- AVG Volume (30 Days)
- ODV 197.3K
- GLSI 29.7K
- Earning Date
- ODV 11-06-2024
- GLSI 10-21-2024
- Dividend Yield
- ODV N/A
- GLSI N/A
- EPS Growth
- ODV N/A
- GLSI N/A
- EPS
- ODV N/A
- GLSI N/A
- Revenue
- ODV $15,873,306.00
- GLSI N/A
- Revenue This Year
- ODV N/A
- GLSI N/A
- Revenue Next Year
- ODV $245.45
- GLSI N/A
- P/E Ratio
- ODV N/A
- GLSI N/A
- Revenue Growth
- ODV N/A
- GLSI N/A
- 52 Week Low
- ODV $1.70
- GLSI $7.58
- 52 Week High
- ODV $3.30
- GLSI $21.44
- Technical
- Relative Strength Index (RSI)
- ODV 50.96
- GLSI 52.23
- Support Level
- ODV $2.03
- GLSI $13.81
- Resistance Level
- ODV $2.19
- GLSI $14.60
- Average True Range (ATR)
- ODV 0.11
- GLSI 0.62
- MACD
- ODV -0.00
- GLSI 0.05
- Stochastic Oscillator
- ODV 30.88
- GLSI 80.77
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation and development activities of its projects.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.